Vertex, Inc. (VERX) has disclosed a new risk, in the Debt & Financing category. Vertex, Inc. faces significant financial risk in the event of a ...

The stock's rise snapped a four-day losing streak.

BMO Capital analyst Daniel Jester lowered the firm’s price target on Vertex (VERX) to $41 from $56 and keeps a Market Perform rating on the shares. The firm had previously indicated that shares had ...

Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday that an expert panel of the EU drug regulator, the European Medicines ...

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...

Vertex, Inc. (NASDAQ:VERX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the company, MarketBeat.com reports.

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

DA Davidson analyst William Jellison lowered the firm’s price target on Vertex (VERX) to $55 from $62 and keeps a Buy rating on the shares.

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

BofA lowered the firm’s price target on Vertex (VERX) to $44 from $55 and keeps a Neutral rating on the shares following Q4 results and an ...

Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, today announced the ...

Arc'teryx’s new footwear models will be available globally, launching throughout 2025. The Norvan LD 4 arrives in March, ...